Literatur
-
1
Dent J, Brun J, Frederick A. et al .
An evidence-based appraisal of reflux disease management - the Genval Workshop Report.
Gut.
1999;
44
Suppl 2
-
2
Carlsson R, Dent J, Watts R. et al .
Gastro-oesophageal reflux disease in primary care: an international study of different tretament strategies with omeprazole.
Eur J Gastroenterol Hepatol.
1998;
10
119-124
-
3
Revicki D A, Crawley J A, Zodet M W. et al .
Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease.
Aliment Pharmacol Ther.
1999;
13
1621-1630
-
4
Bell N J, Burget D, Howden C W. et al .
Appropriate acid suppression for the management of gastroesophageal reflux disease.
Digestion.
1992;
51 (Suppl 1)
59-67
-
5
Chiba N, de Gara C J, Wilkinson J M. et al .
Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis.
Gastroenterology.
1997;
112
1798-1810
-
6
Edwards S J, Lind T, Lundell L.
Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis.
Aliment Pharmacol Ther.
2001;
15
1729-1736
-
7
Wolfe M M, Sachs G.
Acid suppression; Optimizing therapy for gastroduodenal ulcer healing, gastroesohageal reflux disease, and stress-related erosive syndrome.
Gastroenterology.
2000;
118
S9-S31
-
8
Hatlebakk J G, Berstad A.
Gastro-oesophageal reflux during 3 months of therapy with ranitidine in reflux oesophagitis.
Scand J Gastroenterol.
1996;
31
954-958
-
9
Kahrilas P J.
Gastroesophageal reflux disease.
JAMA.
1996;
226
983-988
-
10
Fennerty B M, Castell D, Fendrick M A. et al .
The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment.
Arch Intern Me.
1996;
156
477-484
-
11
Jones R, Bytzer P.
Review article: acid suppression in the management of gastro-oesophageal reflux disease - an appraisal of treatment options in primary care.
Aliment Pharmacol Ther.
2001;
15
765-772
-
12
Isolauri J, Luostarinen M, Isolauri E. et al .
Natural course of gastroesophageal reflux disease: 17 - 22 year follow-up of 60 patients.
Am J Gastroenterol.
1997;
92
37-41
-
13
Singh P, Adamopoulos A, Taylor R H. et al .
Oesophageal motor function before and after healing of oesophagitis.
Gut.
1992;
33
1590-1596
-
14
Eggleston A, Wigerinck A, Hujjghebaert S. et al .
Cost effectiveness of treatment for gastro-oesophageal reflux disease in clinical practice: a clinical database analysis.
Gut.
1998;
42
13-16
-
15
Inadomi J M, Jamal R, Murata G H. et al .
Step-down management of gastroesophaeal reflux disease.
Gastroenterology.
2001;
121
1095-1100
-
16
Koop H, Kuly S, Flug M. et al .
Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects.
Eur J Gastroenterol Hepatol.
1996;
8
915-918
-
17
Peghini P L, Katz P O, Castell D O.
Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects.
Gastroenterology.
1998;
115
1335-1339
-
18
Hendel J, Hendel L, Hage E. et al .
Monitoring of omeprazole treatment in gastrooesophageal reflux disease.
Eur J Gastroenterol Hepatol.
1996;
8
417-420
-
19
Bytzer P.
On-demand therapy for gastro-oesophageal reflux disease.
Eur J Gastroenterol Hepatol.
2001;
13 (Suppl 1)
S19-S22
-
20
Lind T, Havelund T, Lundell L. et al .
On-demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomized trial.
Aliment Pharmacol Ther.
1999;
13
907-914
-
21
Klinkenberg-Knoll E C, Nelis F, Dent J. et al .
Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety and influence on gastric mucosa.
Gastroenterology.
2000;
118
661-669
-
22
Maton P N, Orlando R, Joelsson B.
Efficacy of omeprazole versus ranitidine for symptomatic treatment of poorly responsive acid reflux disease - a prospective controlled trial.
Aliment Pharmacol Ther.
1999;
13
819-826
-
23
Kahrilas P J.
Gastroesophageal reflux disease.
JAMA.
1996;
276
983-988
-
24
Vakil N B, Shaker R, Johnson D A. et al .
The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety.
Aliment Pharmacol Ther.
2001;
15
927-935
-
25
Tytgat G NJ.
Long-term therapy for reflux esophagitis.
N Engl J Med.
1995;
333
1148-1150
-
26
Vigneri S, Termini R, Leandro G. et al .
A comparison of five maintenance therapies for reflux esophagitis.
N Engl J Med.
1995;
333
1106-1110
-
27
Holloway R H, Dent J, Narielvala F. et al .
Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis.
Gut.
1996;
38
649-654
-
28
Carlsson R, Galmiche J P, Dent J. et al .
Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials.
Aliment Pharmacol Ther.
1997;
11
473-482
-
29
Jaspersen D, Diehl K L, Schoeppner H. et al .
A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis.
Aliment Pharmacol Ther.
1998;
12
49-52
-
30
Johnson D A, Benjamin S B, Vakil N B. et al .
Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.
Am J Gastroenterol Hepatol.
2001;
96
27-34
-
31
Dent J, Yeomans N D, Mackinnon M. et al .
Omeprazole vs ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety.
Gut.
1994;
35
590-598
-
32
Hallerbäck B, Unge P, Carling L. et al .
Omeprazole or ranitidine in long-term treatment of reflux esophagitis.
Gastroenterology.
1994;
107
1305-1311
-
33
Laine L, Ahnen D, McClain C. et al .
Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors.
Aliment Pharmacol Ther.
2000;
14
651-668
-
34
Eissele R, Brunner G, Simon B. et al .
Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia.
Gastroenterology.
1997;
112
707-717
-
35
Ben-Rejeb M, Bouche O, Zeitoun P.
Study of 47 consecutive patients with peptic esoohageal stricture compared with 388 cases of reflux esophagitis.
Dig Dis Sci.
1992;
37
733-736
-
36
Marks R D Richte JE, Rizzo J. et al .
Omeprazole vs H-2-receptor antagonists in treating patients with peptic stricture and esophagitis.
Gastroenterlogy.
1994;
106
907-915
-
37
Smith P M, Kerr G D, Cockel R. et al .
A comparison of omeprazole and ranitidine in prevention of recurrence of benign esophageal stricture.
Gastroenterology.
1994;
107
1312-1318
-
38
Kuipers E J, Lundell L, Klinkenberg-Knoll E. et al .
Atrophic gastritis and helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole for fundoplication.
N Engl J Med.
1996;
334
1018-1022
-
39
Schenk B E, Kuipers E J, Nelis G F. et al .
Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy.
Gut.
2000;
46
615-621
-
40
Martinek J, Blum A L, Stolte M. et al .
Effects of pumaprazole (BY841), a novel reversible proton pump antagonist, and of omeprazole, on intragastric acidity before and after cure of Helicobacter pylori infection.
Aliment Pharmacol Ther.
1999;
13
27-34
-
41
Holtmann G, Cain C, Malfertheiner P.
Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole.
Gastroenterology.
1999;
117
11-16
-
42
Lundell L, Miettinen P, Myrvold H E. et al .
Lack of effect of acid suppression therapy on gastric atrophy.
Gastroenterology.
1999;
117
319-326
-
43
Kuipers E J, Klinkenberg-Knol E C, Meuwissen S G.
Helicobacter pylori, proton pump inhibitors and gastroesophageal reflux disease.
Yale J Biol Med.
1999;
72
211-218
-
44
Dent J.
Review article: is Helicobacter pylori relevant in the management of reflux disease?.
Aliment Pharmacol Ther.
2001;
15
16-12
-
45
Hunt R H, Sumanac K, Huang J O.
Review article: should we kill or should we save Helicobacter pylori?.
Aliment Pharmacol Ther.
2001;
15
51-59
1 zugelassene Langzeitdosierungen
